KODIAK SCIENCES INC

Inside Kodiak Sciences’ surge: insider buys, Phase III success of KOD‑001, and FDA/EMA milestones suggest a promising valuation climb for the rare‑disease biotech.

Discover how Kodiak Sciences’ CFO leveraged a 10‑b‑5‑1 plan to buy at $1.04 and sell at $34‑$35, boosting insider confidence while providing liquidity for future trials.

Insightful: Kodiak Sciences CFO buys shares at $1.04—signals insider confidence in retinal‑therapeutics pipeline and upcoming regulatory milestones.

Discover why Kodiak Sciences CFO John Borgeson bought $1.04 shares amid sales, signaling confidence in the biotech’s clinical pipeline and long‑term upside.

CEO Victor Perlroth’s $1.04 buy of 300k Kodiak Sciences shares underscores strong insider confidence amid soaring Phase III results and a looming FDA Zenkuda submission.